New strategy to treat diabetic retinopathy using stabilization of hyalocyte-vasucular endothelial cell correlation
| Project/Area Number |
21592215
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Ophthalmology
|
|---|
| Research Institution | Yamagata University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YAMAMOTO Teiko 山形大学, 医学部, 准教授(現在:要町やまもと眼科医院長) (00297706)
GOTO Sakiko 山形大学, 医学部・眼科学, 助教 (40444038)
KASHIWAGI Yoshiko 山形大学, 医学部, 客員助教(現在:山形県立米沢女子短期大学助手) (90375345)
ABE Sachi 山形大学, 医学部, 医員 (90550658)
|
|---|
| Project Period (FY) |
2009 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2011: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2010: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2009: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 糖尿病黄斑浮腫 / 網膜内境界膜 / 硝子体細胞 / グリア細胞 / 網膜ー硝子体界面 / 血管内皮細胞 / ステロイド / 点眼約治療 / 炎症性サイトカイン / ヒアルロン酸 / ステロイド点眼 / 非観血的治療 / 点眼治療 / 眼内移行 / 網膜-硝子体界面 / 網膜-硝子体海面 |
|---|
| Research Abstract |
Ocular angiogenesis is regulated by polypeptides including cytokines, which are known to affect vascular endothelial cells. We have investigated that hyalocytes interact with vascular endothelial cells, and some cytokines affect these interactions. To determine the effect of various chemically active agents on the viability of endothelial cells alone and cocultured with hyalocytes. The viability of human retinal endothelial cells (HREC_s) was determined after exposure to IL-1α, IL-1β, IL-6, TNFα and VEGF using the MTT assay. These results were compared to the viability when the HRECs were cocultured with porcine hyalocytes that had been exposed to different types of cytokines. The effects of bevacizumab, fenofibrate and dexamethasone on the viability of HRECs in coculture with hyalocytes were also assessed. Ten micrograms/millilitre of bevacizumab decreased the percentage of living HRECs stimulated by VEGF without hyalocytes, but with the hyalocytes, 100 μg/ml of bevacizumab was requir
… More
ed to decrease the percentage of viable HRECs stimulated by VEGF. Dexamethasone at 50 μg/ml, decreased the viability of HRECs stimulated by IL-1α, IL-1β, IL-6 and VEGF without hyalocytes but could not decrease the viability of HRECs cocultured. Coculturing HRECs with vitreous-derived hyalocytes depressed the effects of cytokines, bevacizumab, fenofibrate and dexamethasone. This suggests that the vitreal hyalocytes may play a role in pathogenic endothelial cell proliferation in vivo. In addition, inflammatory processes play important roles in diabetic retinopathy and maculopathy involving hyalocytes and endothelial cells.
Upon the above results, we examined the effects of steroid eye drops to treat diabetic maculopathy. We evaluated the efficacy of treatment refractory diabetic macular edema (DME) after vitrectomy with difluprednate ophthalmic emulsion 0.05% (DurezolR). This study enrolled patients with refractory diabetic macular edema in our clinic. In all subjects, more than 3 months had passed since any prior treatments. The subject eyes were treated with Durezol^(R) 4 times daily for the first month, and then twice daily for 2 months (eye drop group). The mean retinal thickness was improved significantly. Instillation of difluprednate ophthalmic emulsion 0.05% is a safe and effective treatment modality that does not require surgical intervention and does not produce severe side effects. Less
|
Report
(4 results)
Research Products
(22 results)
-
[Journal Article] 糖尿病網膜症の治療戦略2011
Author(s)
山下英俊, 山本禎子, 川崎良, 佐藤浩章, 佐藤さくら, 斉藤公子, 後藤早紀子, 望月典子, 田邉祐資, 桐井枝里子, 阿部さち, 本間慶, 嘉山孝正
-
Journal Title
臨床眼科
Volume: 65
Pages: 1027-1041
NAID
Related Report
-
-
-
-
-
-
-
-
-
[Journal Article]2009
Author(s)
阿部さち、山下英俊
-
Journal Title
糖尿病最新の治療2010-2012(南江堂)
Pages: 181-183
Related Report
-
-
-
-
-
-
-
-
-
-
-
-
